The impact of CYP2E1 genetic variability on risk assessment of VOC mixtures

Regulatory Toxicology and Pharmacology

Volumn 59, Issue 3, 2011, Pages 364-374

  Pohl, Hana R ^a   Scinicariello, Franco ^a  

^a AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY   (United States)

Author keywords

Chemical mixtures; CYP2E1; Genetic polymorphism; VOC interaction

Indexed keywords

1,1,1 TRICHLOROETHANE; 1,2 DICHLOROETHANE; ALDEHYDE DEHYDROGENASE ISOENZYME 2; ARGININE; BENZENE; CHLOROFORM; CYTOCHROME P450 2E1; ETHYLBENZENE; GLUTATHIONE TRANSFERASE; HISTIDINE; ISOLEUCINE; ISONIAZID; PROTEIN P53; TETRACHLOROETHYLENE; TOLUENE; TRICHLOROETHYLENE; VALINE; VINYL CHLORIDE; VOLATILE ORGANIC COMPOUND; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; XYLENE;

AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CARCINOGENICITY; CAUCASIAN; CHEMICAL INTERACTION; COMPETITIVE INHIBITION; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME METABOLISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAZARDOUS WASTE; HEREDITY; HISPANIC; HUMAN; LIVER DISEASE; LIVER TOXICITY; NEGRO; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICOKINETICS;

ANIMALS; CYTOCHROME P-450 CYP2E1; GENETIC VARIATION; HUMANS; ISOENZYMES; RISK ASSESSMENT; VOLATILE ORGANIC COMPOUNDS;

EID: 79952701170     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.01.013     Document Type: Article

References (135)

1. Ade P., Guastadisegni C., Testai E., et al. Multiple activation of chloroform in kidney microsome from male and female DBA/2J mice. J. Biochem. Toxicol. 1994, 9(6):289-295.
2. ATSDR (Agency for Toxic Substances and Disease Registry), 2004. Guidance Manual for the Assessment of Joint Toxic Action of Chemical Mixtures. US DHHS PHS ATSDR Atlanta, GA. http://www.atsdr.cdc.gov/interactionprofiles/ipga.html.
3. Allemand H., Pessayre D., Descatoire V., DeGott C., Feldmann G., Benhamou J.P. Metabolic activation of trichloroethylene into a chemically reactive metabolite toxic to the liver. J. Pharmacol. Exp. Ther. 1978, 204(3):714-723.
4. Anand S.S., Mumtaz M.M., Mehendale H.M. Dose-dependent liver tissue repair after chloroform plus trichloroethylene binary mixture. Basic Clin. Pharmacol. Toxicol. 2005, 96(6):436-444.
5. Andersen M.E., Gargas M.L., Clewell H.J., Severyn K.M. Quantitative evaluation of the metabolic interaction between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. Toxicol. Appl. Pharmacol. 1987, 89(2):149-157.
6. Barton H.A., Creech J.R., Godin C.S., Randall G.M., Seckel C.S. Chloroethylene mixtures: Pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. Toxicol. Appl. Pharmacol. 1995, 130:237-247.
7. Bellward G.D., Chang T., Rodrigues B., McNeill J.H., Maines S., Ryan D.E., Levin W., Thomas P.E. Hepatic cytochrome P-450j induction in the spontaneously diabetic BB rat. Mol. Pharmacol. 1988, 33:140-143.
8. Bolt H.M., Roos P.H., Thier R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int. Arch. Occup. Environ. Health 2003, 76:174-185.
9. Botto F., Seree E., el Khayari S., de Sousa G., Massacrier A., Placidi M., Cau P., Pellet W., Rahmani R., Barra Y. Tissue-specific expression and methylation of the human CYP2E1 gene. Biochem. Pharmacol. 1994, 48:1095-1103.
10. Bouchardy C., Hirvonen A., Coutelle C., Ward P.J., Dayer P., Benhamou S. Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int. J. Cancer 2000, 87:734-740.
11. Bruckner J.V., Kyle G.M., Luthra R., Acosta D., Mehta S.M., Sethuraman S., Muralidhara S. Acute, subacute and subchronic oral toxicity of 1,1,1-trichloroethane in rats. Toxicol. Sci. 2001, 60(2):363-372.
12. Carlson G.P. Enhancement of the hepatoxicity of trichloroethylene by inducers of drug metabolism. Res. Commun. Chem. Pathol. Pharmacol. 1974, 7(3):637-640.
13. Carlson G.P. Effect of phenobarbital and 3-methylcholanthrene pretreatment on the hepatoxicity of 1,1,1-trichloroethane and 1,1,2-trichloroethane. Life Sci. 1973, 13:67-73.
14. Carrière V., Berthou F., Baird S., Belloc C., Beaune P., deWaziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 1996, 6:203-211.
15. Chang M.H., Lindegren M.L., Butler M.A., Chanock S.J., Dowling N.F., Gallagher M., Moonesinghe R., Moore C.A., Ned R.M., Reichler M.R., Sanders C.L., Welch R., Yesupriya A., Khoury M.J. CDC/NCI NHANES III genomics working group. Prevalence in the United States of selected candidate gene variants: third national health and nutrition examination survey, 1991-1994. Am. J. Epidemiol. 2009, 169(1):54-66.
16. Cheung C., Yu A.M., Ward J.M., Krausz K.W., Akiyama T.E., Feigenbaum L., Gonzalez F.J. The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity. Drug Metab. Dispos. 2005, 33:449-457.
17. Cho H.J., Koh W.J., Ryu Y.J., Ki C.S., Nam M.H., Kim J.W., Lee S.Y. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 2007, 87:551-556.
18. Cornish H.H., Ling B.P., Barth M.L. Phenobarbital and organic solvent toxicity. Am. Ind. Hyg. Assoc. J. 1973, 487:492.
19. Daly A.K., Cholerton S., Gregory W., Idle J.R. Metabolic polymorphism. Pharmacol. Ther. 1993, 57(2-3):129-160.
20. Dong Z.G., Hong J.Y., Ma Q.A., Li D.C., Bullock J., Gonzalez F.J., Park S.S., Gelboin H.V., Yang C.S. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats. Arch. Biochem. Biophys. 1988, 263:29-35.
21. Dorne J.L., Walton K., Renwick A.G. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem. Toxicol. 2005, 43(2):203-216.
22. Durand F., Jebrak G., Pessayre D., Fournier M., Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf. 1996, 15:394-405.
23. El-Masri H.A., Constan A.A., Ramsdell H.S., Yang R.S. Physiologically based pharmacodynamic modeling of an interaction threshold between trichloroethylene and 1,1-dichloroethylene in Fischer 344 rats. Toxicol. Appl. Pharmacol. 1996, 141(1):124-132.
24. El-Masri H.A., Tessari J.D., Yang R.S.H. Exploration of an interaction threshold for the joint toxicity of trichloroethylene and 1,1-dichloroethlene: utilization of a PBPK model. Arch. Toxicol. 1996, 70(9):527-539.
25. EPA, 2010. (US Environmental Protection Agency). Indoor air quality. http://www.epa.gov/iaq/.
26. Fairbrother K.S., Grove J., de Waziers I., Steimel D.T., Day C.P., Crespi C.L., Daly A.K. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998, 8:543-552.
27. Fay R.M., Mumtaz M.M. Development of a priority list of chemical mixtures, occurring at 1,188 hazardous waste sites, using HazDat database. Food Chem. Toxicol. 1996, 34:1163-1165.
28. Garte S., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.L., Baranova H., Bathum L., Benhamou S., Boffetta P., Bouchardy C., Breskvar K., Brockmöller J., Cascorbi I., Clapper M.L., Coutelle C., Daly A., Dell'Omo M., Dolzan V., Dresler C.M., Fryer A., Haugen A., Hein D.W., Hildesheim A., Hirvonen A., Hsieh L.L., Ingelman-Sundberg M., Kalina I., Kang D., Kihara M., Kiyohara C., Kremers P., Lazarus P., Le Marchand L., Lechner M.C., van Lieshout E.M., London S., Manni J.J., Maugard C.M., Morita S., Nazar-Stewart V., Noda K., Oda Y., Parl F.F., Pastorelli R., Persson I., Peters W.H., Rannug A., Rebbeck T., Risch A., Roelandt L., Romkes M., Ryberg D., Salagovic J., Schoket B., Seidegard J., Shields P.G., Sim E., Sinnet D., Strange R.C., Stucker I., Sugimura H., To-Figueras J., Vineis P., Yu M.C., Taioli E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 2001, 10:1239-1248.
29. Gillespie R.B., Guttman S.I. Chemical-induced changes in genetic structure of populations: effects on allozymes. Genetics and Ecotoxicology 1999, Taylor and Francis, Philadelphia, PA. V. Forbes (Ed.).
30. Goasduff T., Bellec G., Amet Y., Dreano Y., Menez J.F., Berthou F. P450 2E1 expression in liver, kidney, and lung of rats treated with single or combined inducers. Alcohol 1996, 13:301-308.
31. Goldsworthy T.L., Popp J.A. Chlorinated hydrocarbon-induced peroxisomal enzyme activity in relation to species and organ carcinogenicity. Toxicol. Appl. Pharmacol. 1987, 88:225-233.
32. Gonzalez F.J., Kimura S. Study of P450 function using gene knockout and transgenic mice. Arch. Biochem. Biophys. 2003, 409:153-158.
33. Guengerich F.P., Kim D.-H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 1991, 4:168-179.
34. Haddad S., Béliveau M., Tardif R., Krishnan K. A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. Toxicol. Sci. 2001, 63:125-131.
35. Haddad S., Charest-Tardif G., Tardif R., Krishnan K. Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. Toxicol. Appl. Pharmacol. 2000, 167:199-209.
36. Haddad S., Tardif R., Charest-Tardif G., Krishnan K. Physiological modeling of the toxicokinetics interactions in a quaternary mixture of aromatic hydrocarbons. Toxicol. Appl. Pharmacol. 1999, 161:249-257.
37. Haddad S., Tardif R., Viau C., Krishnan K. A modeling approach to account for toxicokinetics interactions in the calculation of biological hazard index for chemical mixtures. Toxicol. Lett. 1999, 108:303-308.
38. Haufroid V., Buchet J.P., Gardinal S., Lison D. Cytochrome P4502E1 phenotyping by the measurement of the chlorzoxazone metabolic ratio: assessment of its usefulness in workers exposed to styrene. Int. Arch. Occup. Environ. Health 2002, 75:453-458.
39. Hayashi S., Watanabe J., Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J. Biochem. 1991, 110:559-565.
40. Hollstein M., Marion M.J., Lehman T., Welsh J., Harris C.C., Martel-Planche G., Kusters I., Montesano R. P53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994, 15(1):1-3.
41. Hong J.Y., Pan J.M., Gonzalez F.J., Gelboin H.V., Yang C.S. The induction of a specific form of cytochrome P-450 (P-450j) by fasting. Biochem. Biophys. Res. Commun. 1987, 142:1077-1083.
42. Hsieh H.I., Chen P.C., Wong R.H., Wang J.D., Yang P.M., Cheng T.J. Effect of the CYP2E1 genotype on vinyl chloride monomer-induced liver fibrosis among polyvinyl chloride workers. Toxicology 2007, 239(1-2):34-44.
43. Hu Y., Hakkola J., Oscarson M., Ingelman-Sundberg M. Structural and functional characterization of the 5'-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem. Biophys. Res. Commun. 1999, 263:286-293.
44. Hu Y., Oscarson M., Johansson I., Yue Q.Y., Dahl M.L., Tabone M., Arinco S., Albano E., Ingelman-Sundberg M. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol. Pharmacol. 1997, 51:370-376.
45. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Chang S.C., Chiang C.H., Chang F.Y., Lee S.D. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003, 37:924-930.
46. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., Chang F.Y., Lee S.D. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002, 35:883-889.
47. Huang C.Y., Huang K.L., Cheng T.J., Wang J.D., Hsieh L.L. The GST T1 and CYP2E1 genotypes are possible factors causing vinyl chloride induced abnormal liver function. Arch. Toxicol. 1997, 71(8):482-488.
48. Ingelman-Sundberg M., Johansson I., Yin H., Terelius Y., Eliasson E., Clot P., Albano E. Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol 1993, 10:447-452.
49. International Programme on Chemical Safety (IPCS), 2005. Chemical-Specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/Concentration-Response Assessment. Harmonization Project Document No. 2. World Health Organization, Geneva, Switzerland.
50. Isaacs K.K., Evans M.V., Harris T.R. Visualization-based analysis for a mixed-inhibition binary PBPK model: determination of inhibition mechanism. J. Pharmacokinet. Pharmacodyn. 2004, 31(3):215-242.
51. Jaeger R.J., Conolly R.B., Reynolds E.S., Murphy S.D. Biochemical toxicology of unsaturated halogenated monomers. Environ. Health Perspect. 1975, 11:121-128.
52. Kaneko T., Wang P.-Y., Sato A. Enzymes induced by ethanol differently affect the pharmacokinetics of trichloroethylene and 1,1,1-trichloroethane. Occup. Environ. Med. 1994, 51:113-119.
53. Kim R.B., Yamazaki H., Chiba K., O'Shea D., Mimura M., Guengerich F.P., Ishizaki T., Shimada T., Wilkinson G.R. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol. Exp. Ther. 1996, 279(1):4-11.
54. Kim S.H., Ye Y.M., Palikhe N.S., Kim J.E., Park H.S. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 2010, 10:280-290.
55. Koizumi A., Kuami M., Ikeda M. In vivo suppression of 1,1,1-trichloroethane metabolism by co-administered tetrachloroethylene: An inhalation study. Bull. Environ. Contam. Toxicol. 1982, 29:196-199.
56. Lash L.H., Fisher J.W., Lipscomb J.C., Parker J.C. Metabolism of trichloroethylene. Environ. Health Perspect. 2000, 108:177-200.
57. Le Marchand L., Donlon T., Seifried A., Wilkens L.R. Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 2002, 11(10 Pt 1):1019-1024.
58. Le Marchand L., Wilkinson G.R., Wilkens L.R. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol. Biomarkers Prev. 1999, 8:495-500.
59. Lee Mi-Y., Mukherjee N., Pakstis A.J., Khaliq S., Mohyuddin A., Mehdi S.Q., Speed W.C., Kidd J.R., Kidd K.K. Global patterns of variation in allele and haplotype frequencies and linkage disequilibrium across the CYP2E1 gene. Pharmacogenom. J. 2008, 8:349-356.
60. Lee S.W., Chung L.S., Huang H.H., Chuang T.Y., Liou Y.H., Wu L.S. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int. J. Tuberc. Lung Dis. 2010, 14:622-626.
61. Lewis D.F., Bird M.G., Parke D.V. Molecular modelling of CYP2E1 enzymes from rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity. Toxicology 1997, 118:93-113.
62. Li Y., Marion M.J., Zipprich J., Santella R.M., Freyer G., Brandt-Rauf P.W. Gene-environment interactions between DNA repair polymorphisms and exposure to the carcinogen vinyl chloride. Biomarkers 2009, 14(3):148-155.
63. Li Y., Marion M.J., Rundle A., Brandt-Rauf P.W. A common polymorphism in XRCC1 as a biomarker of susceptibility for chemically induced genetic damage. Biomarkers 2003, 8(5):408-414.
64. Lieber C.S. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review. Alcohol Clin Exp Res. 1999, 23:991-1007.
65. Lieber C.S., DeCarli L.M. Hepatic microsomal ethanol-oxidizing system. In vitro characteristics and adaptive properties in vivo. J Biol Chem 1970, 245:2505-2512.
66. Lipscomb J.C., Kedderis G.L. Incorporating human interindividual biotransformation variance in health risk assessment. Sci Total Environ 2002, 288:13-21.
67. Lipscomb J.C., Teuschler L.K., Swartout J., Popken D., Cox T., Kedderis G.L. The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Analysis 2003, 23(6):1221-1237.
68. Lucas D., Farez C., Bardou L.G., Vaisse J., Attali J.R., Valensi P. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 1998, 12:553-558.
69. Lucas D., Ménez C., Girre C., Berthou F., Bodénez P., Joannet I., Hispard E., Bardou L.G., Ménez J.F. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 1995, 5:298-304.
70. Marion M.J., Boivin-Angele S. Vinyl chloride-specific mutations in humans and animals. IARC Sci. Publ. 1999, 150:315-324.
71. Marion M.J., De Vivo I., Smith S. The molecular epidemiology of occupational carcinogenesis in vinyl chloride exposed workers. Int. Arch. Occup. Environ. Health 1996, 68:394-398.
72. Marion M.J., Froment O., Trépo C. Activation of Ki-ras gene by point mutation inhuman liver angiosarcoma associated with vinyl chloride exposure. Mol. Carcinog. 1991, 4(6):450-454.
73. Mastrangelo G., Fedeli U., Fadda E. Increased risk of hepatocellular carcinoma and liver cirrhosis in vinyl chloride workers: synergistic effect of occupational exposure with alcohol intake. Environ. Health Perspect. 2004, 112:1188-1192.
74. McBride O.W., Umeno M., Gelboin H.V., Gonzalez F.J. A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucl. Acids Res. 1987, 15(23):10071.
75. McCall S.N., Jurgens P., Ivanetich K.M. Hepatic microsomal metabolism of the dichloroethanes. Biochem. Pharmacol. 1983, 32(2):207-213.
76. McCarver D.G., Byun R., Hines R.N., Hichme M., Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol. Appl. Pharmacol. 1998, 152:276-281.
77. Mitoma C., Steeger T., Jackson S.E., Wheeler K.P., Rogers J.H., Milman H.A. Metabolic disposition study of chlorinated hydrocarbons in rats and mice. Drug Chem. Toxicol. 1985, 8(3):183-194.
78. Mizoi Y., Yamamoto K., Ueno Y., Fukunaga T., Harada S. Involvement of genetic polymorphism in alcohol and aldehyde dehydrogenase in individual variation of alcohol metabolism. Alcohol Alcohol. 1994, 29(6):707-710.
79. Morgan K., French S.W., Morgan T.R. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 2002, 36:122-134.
80. Morita M., Le Marchand L., Kono S., Yin G., Toyomura K., Nagano J., Mizoue T., Mibu R., Tanaka M., Kakeji Y., Maehara Y., Okamura T., Ikejiri K., Futami K., Maekawa T., Yasunami Y., Takenaka K., Ichimiya H., Imaizumi N. Genetic polymorphisms of CYP2E1 and risk of colorectal cancer: the fukuoka colorectal cancer study. Cancer Epidemiol. Biomarkers Prev. 2009, 18(1):235-241.
81. Moslen M.T., Reynolds E.S., Szabo S. Enhancement of the metabolism and hepatotoxicity of trichloroethylene and perchloroethylene. Biochem. Pharmacol. 1977, 26:369-375.
82. Mostafa A.M., Abdel-Naim A.B., Abo-Salem O., Abdel-Haziz A.H., Hamada F.M. Renal metabolism of acrylonitrile to cyanide: in vitro studies. Pharmacol. Res. 1999, 40:195-200.
83. Mumtaz M.M., Durkin P.R. A weight-of-evidence approach for assessing interactions in chemical mixtures. Toxicol. Ind. Health 1992, 8:377-406.
84. Nakajima T., Elovaara E., Okino T., Gelboin H.V., Klockars M., Riihimaki V., Aoyama T., Vainio H. Different contributions of cytochrome P450 2E1 and P450 2B1/2 to chloroform hepatotoxicity in rat. Toxicol. Appl. Pharmacol. 1995, 133(2):215-222.
85. Nakajima T., Wang R.S., Elovaara E., Park S.S., Gelboin H.V., Vainio H. A comparative study on the contribution of cytochrome P450 isozymes to metabolism of benzene, toluene, and trichloroethylene in rat liver. Biochem. Pharmacol. 1992, 43(2):251-257.
86. Nakajima T., Wang R.-S., Murayama N., Sato A. Three forms of trichloroethylene-metabolizing enzymes in rat liver induced by ethanol, phenobarbital, and 3-methylcholanthrene. Toxicol. Appl. Pharmacol. 1990, 102:546-552.
87. Nakajima T., Okino T., Okuyama S., Kaneko T., Yonekura I., Sato A. Ethanol-induced enhancement of trichloroethylene metabolism and hepatotoxicity: difference from the effect of phenobarbital. Toxicol. Appl. Pharmacol. 1988, 94(2):227-237.
88. Neafsey P., Ginsberg G., Hattis D., Johns D.O., Guyton K.Z., Sonawane B. Genetic polymorphism in CYP2E1: population distribution of CYP2E1 activity. J. Toxicol. Environ. Health B Crit. Rev. 2009, 12:362-388.
89. Neuhaus T., Ko Y.-D., Lorenzen K., Fronhovs S., Harth V., Bröde P., Vetter H., Bolt H.M., Pesch B., Brüning T. Association of cytochrome P450 2E1 polymorphisms and head and neck squamous cell cancer. Toxicol. Lett. 2004, 151:273-282.
90. NIOSH, 2006. Pocket Guide to Chemical Hazards. National Institute for Occupational Safety and Health, US Department of Health and Human Services, Atlanta, Georgia.
91. Nolan R.J., Freshour N.L., Rick D.L., McCarty L.P., Saunders J.H. Kinetics and metabolism of inhaled methyl chloroform (1,1,1-trichloroethane) in male volunteers. Fundam. Appl. Toxicol. 1984, 4:654-662.
92. Nomura F., Itoga S., Uchimoto T., Tomonaga T., Nezu M., Shimada H., Ochiai T. Transcriptional activity of the tandem repeat polymorphism in the 5'-flanking region of the human CYP2E1 gene. Alcohol Clin. Exp. Res. 2003, 27:42S-46S.
93. Okino T., Nakajima T., Nakano M. Morphological and biochemical analyses of trichloroethylene hepatotoxicity: differences in ethanol- and phenobarbital-pretreated rats. Toxicol. Appl. Pharmacol. 1991, 108(3):379-389.
94. Omer B., Ozbek U., Akkose A., Kilic G. Genetic polymorphism of cytochrome P450 2E1 in the Turkish population. Cell Biochem. Funct. 2001, 19:273-275.
95. Persson I., Johansson I., Bergling H., Dahl M.L., Seidegard J., Rylander R., Rannug A., Hogberg J., Sundberg M.I. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett. 1993, 319:207-211.
96. Plaa G.L. Toxic responses of the liver. Casarett and Doull's Toxicology: The Basic Science of Poisons 1986, 236-309. Macmillan Publishing Company, New York. third ed. C.D. Klaassen, M.O. Amdur, J. Doull (Eds.).
97. Pohl H.R., Mumtaz M.M., Fay M., De Rosa C.T. Evaluation of interactions in chemical mixtures. Principals and Practice of Mixtures Toxicology 2010, 443-467. Wiley& Sons, Chichester, UK. M.M. Mumtaz (Ed.).
98. Pohl H.R., Mumtaz M.M., Scinicariello F., Hansen H. Binary weight-of-evidence evaluations of chemical interactions - 15 years of experience. Regul. Toxicol. Pharmacol. 2009, 54(3):264-271.
99. Pohl H.R., Abadin H.G. Chemical mixtures: evaluation of risk for child-specific exposures in a multi-stressor environment. Toxicol. Appl. Pharmacol. 2008, 233:116-125.
100. Pohl L.R., Branchflower R.V., Highet R.J., et al. The formation of diglutathionyl dithiocarbonate as a metabolite of chloroform, bromotrichloromethane, and carbon tetrachloride. Drug Metab. Dispos. 1981, 9:334-339.
101. Powell H., Kitteringham N.R., Pirmohamed M., Smith D.A., Park B.K. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 1998, 8:411-421.
102. Quinones L., Lucas D., Godoy J., Caceres D., Berthou F., Varela N., Lee K., Acevedo C., Martinez L., Aguilera A.M., Gil L. CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett. 2001, 174:35-44.
103. Radike M.J., Stemmer K.L., Bingham E. Effect of ethanol on vinyl chloride carcinogenesis. Environ. Health Perspect. 1981, 41:59-62.
104. Raucy J.L., Lasker J.M., Kraner J.C., Salazar D.E., Lieber C.S., Corcoran G.B. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol. Pharmacol. 1991, 39:275-280.
105. Ryan D.E., Ramanathan L., Iilda S., Thomas P.E., Hainu M., Shively J.E., Lieber C.S., Levin W. Characterisation of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J. Biol. Chem. 1985, 260:6385-6393.
106. Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a Hu Genet systematic review and meta-analysis. Genet. Med. 2005, 7:97-104.
107. Sangrajrang S., Jedpiyawongse A., Srivatanakul P. Genetic polymorphisms of CYP2E1 and GSTM1 in a Thai population. Asian Pac. J. Cancer Prev. 2006, 7(3):415-419.
108. Sato A., Nakajima T., Koyama Y. Effects of chronic ethanol consumption on hepatic metabolism of aromatic and chlorinated hydrocarbons in rats. Brit. J. Ind. Med. 1980, 37:382-386.
109. Schindler J., Li Y., Marion M.J., Paroly A., Brandt-Rauf P.W. The effect of genetic polymorphisms in the vinyl chloride metabolic pathway on mutagenic risk. J. Hum. Genet. 2007, 52(5):448-455.
110. Sikdar N., Mahmud S.A., Paul R.R., Roy B. Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users. Cancer Lett. 2003, 193:33-42.
111. Smith J.H., Hook J.B. Mechanism of chloroform nephrotoxicity. III. Renal and hepatic microsomal metabolism of chloroform in mice. Toxicol. Appl. Pharmacol. 1984, 73511-73524.
112. Song B.J., Veech R.L., Saenger P. Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J. Clin. Endocrinol. Metab. 1990, 71:1036-1040.
113. Spielberg S.P. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphism drug metabolism. J. Pharmacokinet. Biopharm. 1996, 24:509-519.
114. Squillace P.J., Scott J.C., Moran M.J., Nolan B.T., Kolpin D.W. VOCs, pesticides, nitrate, and their mixtures in groundwater used for drinking water in the United States. Environ. Sci. Technol. 2002, 36:1923B-1930B.
115. Stacey N.H. Toxicity of mixtures of trichloroethylene, tetrachloroethylene and 1,1,1-trichloroethylene: similarity of in vitro to in vivo responses. Toxicol. Ind. Health 1989, 5(3):441-450.
116. Sun F., Chen Y., Xiang Y., Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int. J. Tuberc. Lung Dis. 2008, 12:994-1002.
117. Tanaka E., Terada M., Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J. Clin. Pharm. Ther. 2000, 25:165-175.
118. Tardif R., Charest-Tarif G., Brodeur J., Krishnan K. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicol. Appl. Pharmacol. 1997, 144:120-134.
119. Uematsu F., Ikawa S., Kikuchi H., Sagami I., Kanamaru R., Abe T., Satoh K., Motomiya M., Watanabe M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics 1994, 4(2):58-63.
120. Uematsu F., Kikuchi H., Motomiya M., Abe T., Sagami I., Ohmachi T., Wakui A. Association between restriction fragment length polymorphism of the human cytochrome P450 2E1 gene and susceptibility to lung cancer. Jpn. J. Cancer Res. 1991, 82:254-256.
121. Ulusoy G., Arinç E., Adali O. Genotype and allele frequencies of polymorphic CYP2E1 in the Turkish population. Arch. Toxicol. 2007, 81(10):711-718.
122. Umeno M., McBride O.W., Yang C.S., Gelboin H.V., Gonzalez F.J. Human ethanol-inducible P450IIE1: complete senesequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 1988, 27:9006-9013.
123. Vieira I., Pasanen M., Raunio H., Cresteil T. Expression of CYP2E1 in human lung and kidney during development and in full-term placenta: a differential methylation of the gene is involved in the regulation process. Pharmacol. Toxicol. 1998, 83:183-187.
124. Wang S.L., Lee H., Chen K.W., Tsai K.J., Chen C.Y., Lin P. Cytochrome P4502E1 genetic polymorphisms and lung cancer in a Taiwanese population. Lung Cancer 1999, 26(1):27-34.
125. Wang T., Yu H.T., Wang W., Pan Y.Y., He L.X., Wang Z.Y. Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. J. Int. Med. Res. 2010, 38:977-986.
126. Wang A.H., Zhu S.M., Qiu Y.L., Zhu R., Qu Y.B., Li Y.L., Brandt-Rauf P.W., Xia Z.L. CYP2E1 mRNA expression, genetic polymorphisms in peripheral blood lymphocytes and liver abnormalities in Chinese VCM-exposed workers. Int. J. Occup. Med. Environ. Health 2008, 21(2):141-146.
127. Watanabe J., Hayashi S., Nakachi K., Imai K., Suda Y., Sekine T., Kawajiri K. PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucl. Acids Res. 1990, 18(23):7194.
128. Watanabe J., Hayashi S., Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the Rsa1 polymorphism in the 5'-flanking region. J. Biochem. 1994, 116:321-326.
129. Wong R.H., Du C.L., Wang J.D., Chan C.C., Luo J.C., Cheng T.J. XRCC1 and CYP2E1 polymorphisms as susceptibility factors of plasma mutant p53 protein and anti-p53 antibody expression in vinyl chloride monomer-exposed polyvinyl chloride workers. Cancer Epidemiol. Biomarkers Prev. 2002, 11(5):475-482.
130. Wong N.A.C.S., Rae F., Simpson K.J., Murray G.D., Harrison D.J. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. J. Clin. Pathol. Mol. Pathol. 2000, 53:88-93.
131. Wu X., Shi H., Jiang H., Kemp B., Hong W.K., Delclos G.L., Spitz M.R. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 1997, 18(5):967-973.
132. Yamada S., Tang M., Richardson K., Halaschek-Wiener J., Chan M., Cook V.J., Fitzgerald J.M., Elwood R.K., Brooks-Wilson A., Marra F. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009, 10:1433-1445.
133. Yang B.-M., O'Reilly D.A., Demaine A.G., Kingsnorth A.N. Study of polymorphisms in the CYP2E1 gene in patients with alcoholic pancreatitis. Alcohol 2001, 23:91-97.
134. Zhu S.M., Ren X.F., Wan J.X., Xia Z.L. Evaluation in vinyl chloride monomer-exposed workers and the relationship between liver lesions and gene polymorphisms of metabolic enzymes. World J. Gastroenterol. 2005, 11(37):5821-5827.
135. Zhu S.M., Xia Z.L., Wang A.H., Ren X.F., Jiao J., Zhao N.Q., Qian J., Jin L., Christiani D.C. Polymorphisms and haplotypes of DNA repair and xenobiotic metabolism genes and risk of DNA damage in Chinese vinyl chloride monomer (VCM)-exposed workers. Toxicol. Lett. 2008, 178(2):88-94.